Clinical Trials

50 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02298959 2026-04-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02506153 2026-04-13

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3 Active not recruiting

1,301 enrolled 16 charts

Melanoma

NCT04708418 2026-04-13

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

60 enrolled

Melanoma

NCT05913388 2026-04-13

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

92 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT06961006 2026-04-13

INTerpath-012

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

DermatologicHead & NeckThoracic

12 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT04305054 2026-04-08

KEYMAKER-U02

Phase 1/2 Active not recruiting

315 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06099782 2026-04-08

MK-3475A-F11

DermatologicGenitourinaryThoracic

147 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT06984328 2026-04-08

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

1 enrolled

Phase 3 Active not recruiting

Melanoma, Recurrence

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

257 enrolled

Melanoma, Skin Neoplasms

NCT02816021 2026-04-06

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

24 enrolled

Melanoma

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Phase 3 Recruiting

670 enrolled

Melanoma, Skin Neoplasms

NCT02621021 2026-04-01

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

170 enrolled

Melanoma, Skin Neoplasms

NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

DermatologicGenitourinaryThoracic

284 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03620019 2026-03-27

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

25 enrolled 16 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Melanoma

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04074096 2026-03-25

BEPCOME-MB

10 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

10 enrolled

Melanoma

NCT05537740 2026-03-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT03276832 2026-03-19

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Phase EARLY_PHASE1 Completed

7 enrolled 11 charts

Melanoma

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

36 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

DermatologicGenitourinaryGynecologicHead & NeckThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 2 FDA

Uveal Melanoma, Melanoma

NCT02332668 2026-03-16

MK-3475-051

370 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

DermatologicHead & NeckThoracic

161 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06894771 2026-03-16

MK-4700-001

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

5 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07475572 2026-03-16

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Phase 1 Not yet recruiting

120 enrolled

Melanoma

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

DermatologicGastrointestinalGenitourinaryGynecologic

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07287917 2026-03-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

92 enrolled

BreastDermatologic

Breast Neoplasms, Melanoma

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

36 enrolled

Melanoma

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

14 enrolled

Melanoma

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Melanoma, Skin Neoplasms

NCT07448831 2026-03-09

NeoSenti

49 enrolled

Phase 3 Active not recruiting

Melanoma

NCT02362594 2026-03-05

MK-3475-054

1,019 enrolled 16 charts 2 FDA

Melanoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT07436390 2026-03-02

MAK

Phase NA Completed

132 enrolled

Melanoma, Skin Neoplasms

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

540 enrolled

Melanoma, Nevus, Blue

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

2 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

26 enrolled

Melanoma

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT07410676 2026-02-18

EBNK-ST-001